The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
© 2022. The Author(s)..
There is a growing need for systems that efficiently support the work of medical teams at the precision-oncology point of care. Here, we present the implementation of the Molecular Tumor Board Portal (MTBP), an academic clinical decision support system developed under the umbrella of Cancer Core Europe that creates a unified legal, scientific and technological platform to share and harness next-generation sequencing data. Automating the interpretation and reporting of sequencing results decrease the need for time-consuming manual procedures that are prone to errors. The adoption of an expert-agreed process to systematically link tumor molecular profiles with clinical actions promotes consistent decision-making and structured data capture across the connected centers. The use of information-rich patient reports with interactive content facilitates collaborative discussion of complex cases during virtual molecular tumor board meetings. Overall, streamlined digital systems like the MTBP are crucial to better address the challenges brought by precision oncology and accelerate the use of emerging biomarkers.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
Nature cancer - 3(2022), 2 vom: 22. Feb., Seite 251-261 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tamborero, David [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 19.04.2022 Date Revised 10.02.2024 published: Print-Electronic ErratumIn: Nat Cancer. 2022 May;3(5):649. - PMID 35449310 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s43018-022-00332-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337528039 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337528039 | ||
| 003 | DE-627 | ||
| 005 | 20240210232422.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s43018-022-00332-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM337528039 | ||
| 035 | |a (NLM)35221333 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tamborero, David |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2022 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Nat Cancer. 2022 May;3(5):649. - PMID 35449310 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a There is a growing need for systems that efficiently support the work of medical teams at the precision-oncology point of care. Here, we present the implementation of the Molecular Tumor Board Portal (MTBP), an academic clinical decision support system developed under the umbrella of Cancer Core Europe that creates a unified legal, scientific and technological platform to share and harness next-generation sequencing data. Automating the interpretation and reporting of sequencing results decrease the need for time-consuming manual procedures that are prone to errors. The adoption of an expert-agreed process to systematically link tumor molecular profiles with clinical actions promotes consistent decision-making and structured data capture across the connected centers. The use of information-rich patient reports with interactive content facilitates collaborative discussion of complex cases during virtual molecular tumor board meetings. Overall, streamlined digital systems like the MTBP are crucial to better address the challenges brought by precision oncology and accelerate the use of emerging biomarkers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Dienstmann, Rodrigo |e verfasserin |4 aut | |
| 700 | 1 | |a Rachid, Maan Haj |e verfasserin |4 aut | |
| 700 | 1 | |a Boekel, Jorrit |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez-Fernandez, Adria |e verfasserin |4 aut | |
| 700 | 1 | |a Jonsson, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Razzak, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Braña, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a De Petris, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Yachnin, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Baird, Richard D |e verfasserin |4 aut | |
| 700 | 1 | |a Loriot, Yohann |e verfasserin |4 aut | |
| 700 | 1 | |a Massard, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Martin-Romano, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Opdam, Frans |e verfasserin |4 aut | |
| 700 | 1 | |a Schlenk, Richard F |e verfasserin |4 aut | |
| 700 | 1 | |a Vernieri, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Masucci, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Villalobos, Xenia |e verfasserin |4 aut | |
| 700 | 1 | |a Chavarria, Elena |e verfasserin |4 aut | |
| 700 | 0 | |a Cancer Core Europe consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Balmaña, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Apolone, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Caldas, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Bergh, Jonas |e verfasserin |4 aut | |
| 700 | 1 | |a Ernberg, Ingemar |e verfasserin |4 aut | |
| 700 | 1 | |a Fröhling, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Garralda, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Karlsson, Claes |e verfasserin |4 aut | |
| 700 | 1 | |a Tabernero, Josep |e verfasserin |4 aut | |
| 700 | 1 | |a Voest, Emile |e verfasserin |4 aut | |
| 700 | 1 | |a Rodon, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Lehtiö, Janne |e verfasserin |4 aut | |
| 700 | 1 | |a Anand, Shubha |e investigator |4 oth | |
| 700 | 1 | |a Baars, Danny |e investigator |4 oth | |
| 700 | 1 | |a Bajalica-Lagercrantz, Svetlana |e investigator |4 oth | |
| 700 | 1 | |a Baird, Richard |e investigator |4 oth | |
| 700 | 1 | |a Bierkens, Mariska |e investigator |4 oth | |
| 700 | 1 | |a Blomqvist, Lennart |e investigator |4 oth | |
| 700 | 1 | |a Bono, Costanza |e investigator |4 oth | |
| 700 | 1 | |a De Petris, Luigi |e investigator |4 oth | |
| 700 | 1 | |a Doherty, Gary J |e investigator |4 oth | |
| 700 | 1 | |a Forest, Arnauld |e investigator |4 oth | |
| 700 | 1 | |a Fornerone, Valentina |e investigator |4 oth | |
| 700 | 1 | |a Gabaldi, Paola |e investigator |4 oth | |
| 700 | 1 | |a Haglund, Felix |e investigator |4 oth | |
| 700 | 1 | |a Hartman, Johan |e investigator |4 oth | |
| 700 | 1 | |a Horak, Peter |e investigator |4 oth | |
| 700 | 1 | |a Jutzi, Tanja |e investigator |4 oth | |
| 700 | 1 | |a Kasanicki, Mary |e investigator |4 oth | |
| 700 | 1 | |a Kreutzfeldt, Simon |e investigator |4 oth | |
| 700 | 1 | |a Le Cornet, Lucian |e investigator |4 oth | |
| 700 | 1 | |a Lewensohn, Rolf |e investigator |4 oth | |
| 700 | 1 | |a Lindberg, Johan |e investigator |4 oth | |
| 700 | 1 | |a Lopez, Carlos |e investigator |4 oth | |
| 700 | 1 | |a Lundqvist, Andreas |e investigator |4 oth | |
| 700 | 1 | |a Martin, Jose-Ezequiel |e investigator |4 oth | |
| 700 | 1 | |a Meijer, Gerrit |e investigator |4 oth | |
| 700 | 1 | |a Muñoz, Susana |e investigator |4 oth | |
| 700 | 1 | |a Camus, Maud Ngo |e investigator |4 oth | |
| 700 | 1 | |a Nicotra, Claudio |e investigator |4 oth | |
| 700 | 1 | |a Nuciforo, Paolo |e investigator |4 oth | |
| 700 | 1 | |a Oberrauch, Petra |e investigator |4 oth | |
| 700 | 1 | |a Östling, Päivi |e investigator |4 oth | |
| 700 | 1 | |a Pelz, Laura |e investigator |4 oth | |
| 700 | 1 | |a Piris-Gimenez, Alejandro |e investigator |4 oth | |
| 700 | 1 | |a Provenzano, Elena |e investigator |4 oth | |
| 700 | 1 | |a Rouleau, Etienne |e investigator |4 oth | |
| 700 | 1 | |a Rowell, John |e investigator |4 oth | |
| 700 | 1 | |a Saavedra, Omar |e investigator |4 oth | |
| 700 | 1 | |a Scoazec, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Seamon, Kenneth |e investigator |4 oth | |
| 700 | 1 | |a Tischkowitz, Marc |e investigator |4 oth | |
| 700 | 1 | |a van der Kolk, Lizet |e investigator |4 oth | |
| 700 | 1 | |a van der Noll, Ruud |e investigator |4 oth | |
| 700 | 1 | |a Vieito, Maria |e investigator |4 oth | |
| 700 | 1 | |a Vis, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Vivancos, Ana |e investigator |4 oth | |
| 700 | 1 | |a von Gertten, Christina |e investigator |4 oth | |
| 700 | 1 | |a Wennborg, Anders |e investigator |4 oth | |
| 700 | 1 | |a Wessels, Lodewyk |e investigator |4 oth | |
| 700 | 1 | |a Wirta, Valtteri |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Nature cancer |d 2020 |g 3(2022), 2 vom: 22. Feb., Seite 251-261 |w (DE-627)NLM307030067 |x 2662-1347 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2022 |g number:2 |g day:22 |g month:02 |g pages:251-261 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s43018-022-00332-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2022 |e 2 |b 22 |c 02 |h 251-261 | ||